Compare IDEXX Laboratories, Inc. (IDXX) vs ArcelorMittal SA (MT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs ArcelorMittal SA — how do they compare? IDEXX Laboratories, Inc. trades at $517.91 (market cap $40.43B), while ArcelorMittal SA trades at $64.36 (market cap $45.70B). The key difference: IDEXX Laboratories, Inc. and ArcelorMittal SA are close in size by market cap, and ArcelorMittal SA pays a 0.98% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and ArcelorMittal SA for 36 Days on average.
| IDXX | MT | |
|---|---|---|
Market Cap | $40.43B | $45.70B |
Volume | 692,164 | 1,964,621 |
Sector | Health | Basic Materials |
52-Week High | $766.68 | $78.74 |
52-Week Low | $504.70 | $36.91 |
Typical Hold Time | 46 Days | 36 Days |
Enterprise Value | $41.32B | $55.27B |
Dividend Yield | — | 0.98% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $517.47, up 2.13% with strong earnings momentum after beating Q2 2026 estimates. The stock shows bearish technical signals but maintains robust fundamentals with 25.03% net margins and 74.21% ROE. Recent acquisitions like CoVetAI and expanded diagnostic platforms highlight growth initiatives, while analyst consensus remains bullish with a $665 price target representing 28.5% upside potential.
The outlook remains positive given consistent earnings beats and expanding veterinary diagnostics market share. Key risks include FX headwinds, weaker U.S. vet visits, and premium valuations at 36x P/E. Institutional ownership trends show mixed activity with recent insider selling, but long-term growth drivers in pet healthcare innovation support the bullish analyst stance.
ArcelorMittal (MT) trades at $62.32, down 4.4% on the day, amid a bearish technical setup and recent operational disruptions in Ukraine. The stock shows mixed fundamentals with a low P/S of 0.75 and P/B of 0.84, but profitability metrics like net margin (2.88%) and ROE (3.32%) remain modest. Recent Q2 2026 earnings missed estimates, though Q1 and Q4 2025 beat expectations. Analyst consensus is bullish with a $74.33 price target, but technical indicators signal caution.
The outlook is clouded by near-term headwinds including the Ukraine plant impairment and volatile steel demand, yet long-term value is supported by low valuation multiples and strategic regionalization efforts. Risks include geopolitical exposure and cyclical industry pressures, but institutional sentiment remains positive with 52% buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About ArcelorMittal SA
ArcelorMittal SA is involved in the steel industry. The company's operating segments include NAFTA
Read more on MT →
